Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q2 FY2025-26 Earnings Presentation
16 slides from Gujarat Themis Biosyn's earnings presentation, Nov 10, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2025-26/35 10th November, 2025 Corporate Relationship Department Listing Departmen
Slide 2: Investor Presentation Q2 & H1 FY2025-26
Gujarat Themis Biosyn Limited Investor Presentation Q2 & H1 FY2025-26
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Management Comment
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said: “We are glad to report strong performance in the second quarter of this fiscal year. We achieved relatively higher production and sales volumes vis-à-vis the previous corresponding quarter.
Slide 5: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 39.5 42.4 34.7 37.7 35.9 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 60% 47.7% 49.5% 44.3% 16 32.8% 40% 20 42.5% 50% 33.7% 14 30.4% 31.8% 35% 38.8% 40% 12 25.2% 30% 1
Slide 6: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Rs. Cr. Q2 FY26 Q2 FY25 YoY% Q1 FY26 Income from Operations 42.35 34.72 35.87 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 42.35 34.72 21.98% 35.87 Cost of Materials Consumed 6.92 6.21 6.83 Changes In Inventory (1.5
Slide 7: Half Yearly Financial Highlights
Click to edit Half Master Yearly title Highlights Financial style Rs. Crs H1 FY26 H1 FY25 YoY% Income from Operations 78.22 73.54 Other Operating Income 0.00 0.00 Total Income from Operations 78.22 73.54 6.36% Cost of Materials Consumed 13.75 12.37 Changes In Inventory (1.73) (1.09) Employee Cost 7.
Slide 8: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 169.82 148.39 150.80 114.85 90.56 FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 90 50.5% 49.6% 51% 46.4% 80 50% 70 39.1% 45% 45.7% 38.0% 70 49% 34.8% 40% 60 33.3% 32.3% 60 48
Slide 9: Balance Sheet Highlights – As on 30th September 2025
Click to edit Master Balance title style– As on 30th September 2025 Sheet Highlights Rs. Cr. As on 30th As on 31st Rs. Cr. As on 30th As on 31st Mar, Total Equity & Liabilities Sep, 2025 Mar, 2025 Total Assets Sep, 2025 2025 Shareholders Funds 264.43 248.38 Non Current Assets 321.87 249.34 Share Cap
Slide 10: Key Balance Sheet Ratios
Keyedit Click to Balance Sheet Master Ratios title style RoCE(%)* RoA(%)** 35.6% 34.9% 57.9% 26.8% 52.1% 39.4% 16.2% 23.6% FY21-22 FY22-23 FY23-24 FY24-25 FY21-22 FY22-23 FY23-24 FY24-25 RoE(%)*** 42.2% 38.9% 29.4% 19.6% FY21-22 FY22-23 FY23-24 FY24-25 Company has been investing in Capex over last t
Slide 11: Among India's few fermentation based Intermediate manufacturers
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility ▪ Incorporated in 1981 as joint ▪ Plant in Vapi (Gujarat) sector Company with GIIC
Slide 12: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin ▪ An intermediate for Rifamycin S ▪ An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 13: Expansion Strategy to Spur Growth
Click to edit Master Expansion titletostyle Strategy Spur Growth Capex Plan Research & Development Forward Integration Fermentation ❖ Ventured into API production as ❖ New Product Development part of forward integration ❖ Expanding fermentation capacity ❖ R&D Unit Commissioned, as per strategy ❖ Add
Slide 14: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 13
Slide 15: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style ▪ In process of identifying new products which have good domestic & export New Product Development & potential ▪ Company strategizing to move up the value chain through forward integration into Forward Integration API – recently began commercial operation
Slide 16: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan Mr. Rahul Trivedi Mr. Vivek Sahu pradeep.chandan@themismedicare.com rahul.trivedi@adfactorspr.com vivek.
Gujarat Themis Biosyn — Q2 FY2025-26 Earnings Presentation on 6ix